Phreesia (NYSE:PHR) Insider David Linetsky Sells 1,064 Shares

Key Points

• David Linetsky sold 1,064 shares of Phreesia stock at an average price of $23.50, totaling approximately $25,004, reducing his ownership to 173,888 shares valued at around $4.09 million.
• Phreesia reported a quarterly revenue increase of 14.9% year-over-year, with earnings per share of $0.01, beating the consensus estimate, and it's guided for a loss of $1.1 EPS for the current fiscal year.
• Several research firms upgraded Phreesia's stock rating, with JMP Securities raising the price target from $30.00 to $34.00, while Canaccord Genuity increased theirs from $34.00 to $38.00, indicating a robust outlook for the company.

Phreesia, Inc. (NYSE:PHR - Get Free Report) insider David Linetsky sold 1,064 shares of the business's stock in a transaction that occurred on Wednesday, September 17th. The stock was sold at an average price of $23.50, for a total value of $25,004.00. Following the transaction, the insider owned 173,888 shares of the company's stock, valued at approximately $4,086,368. This represents a 0.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

David Linetsky also recently made the following trade(s):

• On Thursday, September 18th, David Linetsky sold 93 shares of Phreesia stock. The shares were sold at an average price of $23.94, for a total value of $2,226.42.
• On Tuesday, September 16th, David Linetsky sold 2,165 shares of Phreesia stock. The stock was sold at an average price of $23.28, for a total value of $50,401.20.
• On Friday, August 22nd, David Linetsky sold 17,445 shares of Phreesia stock. The shares were sold at an average price of $29.73, for a total transaction of $518,639.85.
• On Monday, August 18th, David Linetsky sold 78 shares of Phreesia stock. The shares were sold at an average price of $29.16, for a total transaction of $2,274.48.
• On Thursday, July 17th, David Linetsky sold 2,063 shares of Phreesia stock. The stock was sold at an average price of $26.89, for a total transaction of $55,474.07.
• On Friday, June 27th, David Linetsky sold 23,729 shares of Phreesia stock. The shares were sold at an average price of $28.50, for a total transaction of $676,276.50.

Phreesia Price Performance

PHR traded up $0.87 during trading on Monday, reaching $24.74. The stock had a trading volume of 1,065,169 shares, compared to its average volume of 1,230,749. Phreesia, Inc. has a 1-year low of $17.07 and a 1-year high of $32.76. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of -58.90 and a beta of 0.72. The stock has a 50 day moving average of $27.51 and a two-hundred day moving average of $26.40. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.02.

Phreesia (NYSE:PHR - Get Free Report) last announced its quarterly earnings data on Thursday, September 4th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.08. The business had revenue of $117.26 million during the quarter, compared to analyst estimates of $116.39 million. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.The company's revenue was up 14.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.03) earnings per share. Phreesia has set its FY 2026 guidance at EPS. As a group, equities analysts anticipate that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PHR has been the topic of a number of research reports. Wall Street Zen upgraded shares of Phreesia from a "hold" rating to a "buy" rating in a report on Sunday, June 1st. Needham & Company LLC increased their price objective on Phreesia from $29.00 to $35.00 and gave the company a "buy" rating in a research report on Friday, September 5th. Raymond James Financial set a $33.00 target price on Phreesia and gave the stock an "outperform" rating in a report on Friday, September 5th. DA Davidson raised Phreesia to a "strong-buy" rating in a research report on Monday, September 8th. Finally, JMP Securities raised their target price on shares of Phreesia from $30.00 to $34.00 and gave the stock a "market outperform" rating in a report on Monday, September 8th. One analyst has rated the stock with a Strong Buy rating and twelve have assigned a Buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $34.08.

Institutional Trading of Phreesia

Several institutional investors have recently modified their holdings of PHR. Raymond James Financial Inc. boosted its position in shares of Phreesia by 2.7% during the 2nd quarter. Raymond James Financial Inc. now owns 14,049 shares of the company's stock valued at $400,000 after acquiring an additional 375 shares in the last quarter. Diversified Trust Co boosted its stake in Phreesia by 1.0% in the second quarter. Diversified Trust Co now owns 45,042 shares of the company's stock valued at $1,282,000 after acquiring an additional 426 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of Phreesia by 2.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 19,983 shares of the company's stock valued at $569,000 after acquiring an additional 540 shares during the period. Arcadia Investment Management Corp MI grew its stake in Phreesia by 0.7% in the first quarter. Arcadia Investment Management Corp MI now owns 92,770 shares of the company's stock valued at $2,371,000 after acquiring an additional 615 shares during the period. Finally, Oppenheimer Asset Management Inc. increased its position in shares of Phreesia by 9.9% during the second quarter. Oppenheimer Asset Management Inc. now owns 8,803 shares of the company's stock worth $251,000 after acquiring an additional 792 shares in the last quarter. Institutional investors and hedge funds own 92.10% of the company's stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.